참고문헌
- Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. Drug Discov Today 2005;10:1313-21 https://doi.org/10.1016/S1359-6446(05)03552-X
- Davis JM, Elfenbein J, Schum R, Bentler RA. Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. J Speech Hear Disord 1986;51:53-62
- Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005;23:8588-96 https://doi.org/10.1200/JCO.2004.00.5355
- Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 1991;19:295-300 https://doi.org/10.1002/mpo.2950190415
- Parsons SK, Neault MW, Lehmann LE, Brennan LL, Eickhoff CE, Kretschmar CS, et al. Severe ototoxicity following carboplatin- containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 1998;22:669-74 https://doi.org/10.1038/sj.bmt.1701391
- Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004;40:2445-51 https://doi.org/10.1016/j.ejca.2003.08.009
- Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE. Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 2009;52:387-91 https://doi.org/10.1002/pbc.21875
- Fujimoto T. Current status in treatment of childhood cancer. Gan To Kagaku Ryoho 1995;22:1295-301
- Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear 1998;19:339-54 https://doi.org/10.1097/00003446-199810000-00001
- Tharpe AM, Bess FH. Minimal, progressive, and fluctuating hearing losses in children. Characteristics, identification, and management. Pediatr Clin North Am 1999;46:65-78 https://doi.org/10.1016/S0031-3955(05)70081-X
- Clerici WJ, Hensley K, DiMartino DL, Butterfield DA. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear Res 1996;98:116-24 https://doi.org/10.1016/0378-5955(96)00075-5
- Dehne N, Lautermann J, Petrat F, Rauen U, de Groot H. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol 2001;174:27-34 https://doi.org/10.1006/taap.2001.9171
- van Ruijven MW, de Groot JC, Klis SF, Smoorenburg GF. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res 2005;205:241-8 https://doi.org/10.1016/j.heares.2005.03.023
- Kopke RD, Liu W, Gabaizadeh R, Jacono A, Feghali J, Spray D, et al. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatininduced damage of auditory hair cells. Am J Otol 1997;18: 559-71
- McHaney VA, Thibadoux G, Hayes FA, Green AA. Hearing loss in children receiving cisplatin chemotherapy. J Pediatr 1983;102:314-7 https://doi.org/10.1016/S0022-3476(83)80551-4
- Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 1989;7:754-60
- Skinner R, Pearson AD, Amineddine HA, Mathias DB, Craft AW. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer 1990;61:927-31
- Pasic TR, Dobie RA. cis-platinum ototoxicity in children. Laryngoscope 1991;101:985-91
- Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006;107:417-22 https://doi.org/10.1002/cncr.22004
- Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004;26:649-55 https://doi.org/10.1097/01.mph.0000141348.62532.73
- Ilveskoski I, Saarinen UM, Wiklund T, Perkkio M, Salmi TT, Lanning M, et al. Ototoxicity in children with malignant brain tumors treated with the '8 in 1' chemotherapy protocol. Med Pediatr Oncol 1996;27:26-31 https://doi.org/10.1002/(SICI)1096-911X(199607)27:1<26::AID-MPO6>3.0.CO;2-W
- Stohr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, et al. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest 2005;23:201-7 https://doi.org/10.1081/CNV-200055951
- Murakami T, Inoue S, Sasaki K, Fujimoto T. Studies on agedependent plasma platinum pharmacokinetics and ototoxicity of cisplatin. Sel Cancer Ther 1990;6:145-51 https://doi.org/10.1089/sct.1990.6.145
- Chen WC, Jackson A, Budnick AS, Pfister DG, Kraus DH, Hunt MA, et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 2006;106:820-9 https://doi.org/10.1002/cncr.21683
- Gabaizadeh R, Staecker H, Liu W, Kopke R, Malgrange B, Lefebvre PP, et al. Protection of both auditory hair cells and auditory neurons from cisplatin induced damage. Acta Otolaryngol 1997;117:232-8 https://doi.org/10.3109/00016489709117778
- Choe WT, Chinosornvatana N, Chang KW. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol 2004;25:910-5 https://doi.org/10.1097/00129492-200411000-00009
- Lee JE, Nakagawa T, Kim TS, Endo T, Shiga A, Iguchi F, et al. Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment. Acta Otolaryngol 2004;124:1131-5 https://doi.org/10.1080/00016480410017521
- Whitworth CA, Ramkumar V, Jones B, Tsukasaki N, Rybak LP. Protection against cisplatin ototoxicity by adenosine agonists. Biochem Pharmacol 2004;67:1801-7 https://doi.org/10.1016/j.bcp.2004.01.010
- Lynch ED, Gu R, Pierce C, Kil J. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 2005;201:81-9 https://doi.org/10.1016/j.heares.2004.08.002
- Lynch ED, Gu R, Pierce C, Kil J. Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing antitumor activity. Anticancer Drugs 2005;16:569-79 https://doi.org/10.1097/00001813-200506000-00013
- Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T, et al. Amifostine protects against cisplatininduced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 2008;26:3749-55 https://doi.org/10.1200/JCO.2007.14.3974
- Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol 2008;30:130-4 https://doi.org/10.1097/MPH.0b013e31815d1d83